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Objective: Neurotoxicity is the most frequent dose-limiting side effect of the anti-
cancer agent oxaliplatin, but the mechanisms are not well understood. This study used 
nerve excitability testing to investigate the pathophysiology of the acute 
neurotoxicity.  
Methods: Questionnaires, quantitative sensory tests, nerve conduction studies and 
nerve excitability testing were undertaken in 12 patients with high-risk colorectal 
cancer treated with adjuvant oxaliplatin and in 16 sex- and age-matched healthy 
controls. Examinations were performed twice for patients: once within 3 days after 
oxaliplatin treatment (post-infusion examination) and once shortly before the 
following treatment (recovery examination). 
Results: The most frequent post-infusion symptoms were tingling paresthesias and 
cold allodynia. The most prominent nerve excitability change was decreased 
superexcitability of motor axons which correlated with the average intensity of 
abnormal sensations (Spearman Rho=0.80, p<0.01). The motor nerve excitability 
changes were well modeled by a slowing of sodium channel inactivation, and were 
proportional to dose/m2 with a half-life of about 10d. 
Conclusions: Oxaliplatin induces reversible slowing of sodium channel inactivation 
in motor axons, and these changes are closely related to the reversible cold allodynia. 
However, further studies are required due to small sample size in this study.  
Significance: Nerve excitability data provide an index of sodium channel 
dysfunction: an objective biomarker of acute oxaliplatin neurotoxicity.  
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- Symptoms after oxaliplatin infusion correlate with nerve excitability findings.  
- Oxaliplatin induces a slowing of sodium channel inactivation in motor nerve 
fibres. 






Oxaliplatin is a third-generation platinum analog used for the treatment of solid 
cancers, in particular as primary and adjuvant treatment of advanced and high-risk 
colorectal cancer (DCCG, 2015). Neurotoxicity is a frequent and often dose-limiting 
side effect of oxaliplatin treatment (Gamelin et al., 2002, Argyriou et al., 2013). 
Oxaliplatin is unique among platinum analogs, as it induces two clinically different 
types of peripheral neuropathy. One type is a commonly occurring acute neurotoxicity 
with transient paresthesia, typically triggered by cold exposure, and muscle spasms in 
the limbs and jaw. The symptoms develop immediately during infusion and usually 
resolve within days and before the next cycle of oxaliplatin. Symptoms may increase 
in both severity and duration with repeated administrations (Pachman et al., 2015). 
Acute transient symptoms occur in nearly all patients (Wilson et al., 2002; Argyriou 
et al., 2013; Ventzel et al., 2015, 2016). In contrast, the second type, which is a 
chronic neuropathy, develops with increasing cumulative dose (Beijers et al., 2014, 
2015) and is characterized by sensory loss and paresthesia in a stocking and glove-
distribution, eventually progressing to sensory ataxia (Land et al., 2007; Mols et al., 
2013; Beijers et al., 2014, 2015).  
Conventional nerve conduction studies (NCS) cannot be used to assess early nerve 
dysfunction (Lehky et al., 2004) and do not reveal abnormalities until axonal loss or 
demyelination or both are well established, i.e. weeks or months after exposure to a 
neurotoxic drug. Nerve excitability testing provides complementary information to 
conventional NCS and may be used to infer the activity of a variety of ion channels, 
energy-dependent pumps, and ion exchange processes activated during the process of 
impulse conduction (Krishnan et al., 2009; Barnes, 2012; Kiernan et al., 2013).  
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The pathophysiological mechanisms of acute oxaliplatin-induced peripheral 
neuropathy are not yet fully understood. Studies examining axonal excitability tests 
(Bostock et al., 1998; Kiernan et al., 2000) have suggested abnormal functioning of 
axonal voltage-gated Na+ channels in both motor and sensory axons in patients in the 
acute phase following oxaliplatin treatment (Park et al., 2009a, 2009b, 2011; Park et 
al., 2012). However, these changes have not been correlated to patients’ symptoms.  
The purpose of the present study was to investigate the underlying mechanisms of 
acute oxaliplatin-induced neuropathy by examining sensory and motor axonal 
excitability changes and correlating these to sensory symptoms and signs. Excitability 
parameters in the acute phase were compared to parameters after partial recovery and 
to healthy controls, and mathematical modeling of the excitability changes was used 
to provide an objective index of sodium channel dysfunction. 
 
2. Methods 
2.1. Study population 
Patients were consecutively recruited from the Department of Oncology, Aarhus 
University Hospital, Denmark, from May 2015 to January 2016. All patients of at 
least 18 years and treated with standard adjuvant oxaliplatin (XELOX) after high-risk 
colorectal cancer (stage II or stage III) (DCCG, 2015) or enrolled in a protocol 
receiving two cycles of XELOX as neoadjuvant treatment were eligible. Sex- and 
age-matched healthy controls were recruited by announcement. Patients with 
conditions that might cause neuropathy (other than the current oxaliplatin treatment) 
such as known metastatic cancer, previous treatment with chemotherapy, diabetes, 
renal failure, medicine that may induce neuropathy, alcohol abuse, chronic pain not 
related to the oxaliplatin treatment above 5 on a 0-10 numerical rating scale (NRS), 
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and patients who did not read, speak, or understand Danish were excluded. Healthy 
controls were excluded if they had clinical signs of carpal tunnel syndrome or had 
used analgesics in the past 7 days. NCS of the median nerve were performed in both 
patients and healthy controls, and subjects were excluded if they had 
electrophysiological signs of carpal tunnel syndrome.  
All subjects gave written informed consent to the procedures, and the study was 
approved by the Danish National Committee on Biomedical Research Ethics in 
Central Denmark Region (no. 1-10-72-414-14) and the Danish Data Protection 
Agency (no 1-16-02-279-15). 
2.2. Study design 
Patients were recruited while they were hospitalized to receive one of the first cycles 
of chemotherapy. The XELOX regimen included oxaliplatin (130 mg/m2) given 
intravenously over 2 hours every 3 weeks followed by oral capecitabine (1000 mg/m2) 
twice a day for 14 days. Patients receiving two cycles of neoadjuvant oxaliplatin were 
examined through one of the first two cycles of chemotherapy before surgery.  
The first examination was performed within the first 3 days after one of the first three 
cycles of oxaliplatin (post-infusion examination). The second examination was 
performed in the last week before the next cycle (recovery examination), which 
corresponded to a 2-week interval. Patients receiving neoadjuvant oxaliplatin were 
examined again before the next cycle. One patient discontinued chemotherapy and 
was scheduled for surgery; in this case the second examination was done after surgery 
and 53 days after the first examination. No patients received chemotherapy between 
the first and second examination. One patient died before the second examination, and 
recovery data were therefore obtained from 11 patients.  




2.3. Clinical examination and questionnaires 
At the first examination, patients’ medical history was obtained and clinical and 
neurological examinations were performed. Patients were asked if they had 
experienced new onset pain or non-painful abnormal sensations (paresthesia or 
dysesthesia) during the past 24 hours, and the average intensity during the past 24 
hours was assessed using an NRS (Numerical Rating Scale) ranging from 0 to 10, 
with 0 being no pain/abnormal sensations and 10 being the worst pain/sensation 
imaginable. The patients completed the Neuropathic Pain Symptom Inventory (NPSI 
© 2004. Bouhassira D, all rights reserved), which is a self-administered questionnaire 
specifically designed to evaluate different symptoms of neuropathic pain (Bouhassira 
et al., 2004), and a specific questionnaire for assessing chemotherapy-induced sensory 
symptoms addressing the upper extremity, the lower extremity, and the orofacial area 
(Leonard et al., 2005).  
 
2.4. Sensory examination 
The temperature in the examination room was kept between 21C and 25C, and the 
basal skin temperature was measured with an infrared thermometer at the site of 
examination. 
Cold-evoked symptoms were assessed using a cold metal cylinder (Ventzel cylinder, 
Denmark). Participants lifted and held a solid metal cylinder, which had been kept in 
the refrigerator for at least 12 hours, in the hand for 10 seconds (temperature ~ 6C) 
(Ventzel et al., 2015). Hereafter, the participants rated the cylinder as either freezing 
cold, cold, neutral, warm or burning warm. The participants also rated pain, 
unpleasantness, and pricking on the NRS (0-10). 
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Quantitative sensory testing (QST) was done with the patient lying relaxed in a bed in 
a quiet room during daytime. Tests were performed at the thenar eminence of the 
dominant hand. Using the QST protocol of the German Research Network on 
Neuropathic Pain (DFNS) (Rolke et al., 2006a), the following parameters were tested: 
vibration detection threshold (VDT), cold detection threshold (CDT), cold pain 
threshold (CPT), warm detection threshold (WDT), heat pain threshold (HPT), 
thermal sensory limen (TSL), and mechanical pain threshold (MPT). Thermal stimuli 
were applied using the Thermal Sensory Analyzer (TSA, Medoc, Israel) with a 
contact area of 3 x 3 cm and cut-off temperatures of 0C and 50C (Rolke et al., 
2006b). All parameters were determined by repeated measurements as outlined within 
the standardized and validated QST protocol (Rolke et al., 2006a).  
 
2.5. Neurophysiological examinations 
Neurophysiological examinations were undertaken with the subject comfortably 
seated or lying in a bed with the arm placed on a pillow for examination. The 
subject’s hand and forearm were cleansed with Nuprep skin prep gel and alcohol. 
2.5.1. Nerve conduction studies 
Conventional sensory and motor NCS of the median nerve were undertaken using the 
surface electrode technique. Keypoint EMG equipment version 2.11 (Dantec, 
Skovlunde, Denmark) was used. The evaluated sensory NCS parameters were the 
conduction velocity, duration and base to peak amplitude in the second or third digit 
with antidromic stimulation. The motor NCS parameters recorded in the abductor 
pollicis brevis muscle were distal motor latency, conduction velocity at forearm, peak 
to peak amplitude, duration and minimum F-wave latency. The duration of the 
9 
 
compound sensory nerve and muscle action potentials was determined at 50% of the 
base to peak amplitude. 
2.5.2. Nerve excitability tests 
Motor and sensory nerve excitability tests were done in the median nerve. Stimulation 
at the wrist and recording from abductor pollicis brevis muscle were controlled by the 
Qtrac software (Institute of Neurology, University College London, London, 
distributed by Digitimer Ltd at www.digitimer.com) and stimulus current was applied 
using an isolated linear bipolar constant current stimulator (DS5, Digitimer Ltd). 
Stimulations were made with non-polarizable electrodes and an anode electrode 
placed 10 cm proximal to the stimulation electrode, not over the nerve. A ground 
electrode was placed at the dorsum of the hand. Compound motor action potentials 
(CMAP) were recorded in the abductor pollicis brevis muscle with the active 
electrode over the motor point and a reference electrode placed 4 cm distally. 
Compound sensory action potentials (CSAP) were recorded from the second digit (in 
one patient the third digit due to amputation of the second digit) using Velcro ring 
electrodes placed at the proximal and distal interphalangeal joints for recording and 
reference, respectively. The skin temperature was measured and kept above 32C. 
Multiple excitability measurements were made with the TRONDNF protocol, in 
which 'thresholds' were tracked as the stimuli required to elicit a target response 
amplitude that was 40% of maximal. The measurements comprised: 1) strength 
duration time constant (SDTC), 2) threshold electrotonus (TE) with 100 ms polarizing 
currents set to +/-40% and +/- 20% of control threshold current, 3) recovery cycle of 
percentage changes in threshold following a supramaximal stimulus (RC) and 4) 
current–threshold relationship (I/V), consisting of the threshold changes after 200 ms 
of polarizing current, varied between 50% and -100% of control threshold current.  
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Additionally, in a subset of the healthy control subjects, recovery cycles were 
recorded with two supramaximal conditioning stimuli, 4 ms apart, using the RC2C 
option in the TRONDNF protocol. Superexcitability was measured by the QtracP 
software as the minimum mean of 3 adjacent points in the recovery cycle for inter-
stimulus intervals less than 12 ms, and subexcitability as the maximum mean of 3 
adjacent points at longer intervals and relative refractory period (RRP) as the 
interpolated  inter-stimulus interval at which the nerve first became superexcitable. In 
the case that the nerve never became superexcitable, superexcitability was scored as 
zero and RRP was undefined. 
2.5.3. Modeling of nerve excitability data 
To aid interpretation of the nerve excitability data, the full set of excitability 
measurements was compared with a previously established mathematical model, 
which interprets the waveforms recorded as due to the interaction of membrane 
potential and nodal and internodal ion channels (Kiernan et al., 2005; Howells et al., 
2012; Boerio et al., 2014). The MEMFITS option in the Qtrac software was used to 
find the changes in the normal motor axon model that best fitted the mean post-
infusion recordings from motor axons, using a least squares method (Kiernan et al., 
2005). For each measurement in the Trond protocol, the discrepancy between the 
model and the recordings was calculated as: [(xm -xn)/sn] 2, where xm is the 
threshold of the model, xn the mean and sn the standard deviation of the thresholds 
for the real nerves. The weights for the measurements within each test were the same 
but the weights for each test were different (strength-duration relationship = 0.5, 
threshold electrotonus = 2, current/threshold relationship = 1, recovery cycle = 1). 
Accordingly, the recently published model of motor nerve excitability (Howells et al., 
2012) was first adjusted by small changes to all parameters to optimize the fit to the 
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healthy control recordings. Then, each parameter in the model was tested in turn to 
see how well it reduced the discrepancy between the recordings and the model, 
calculated as described above. The parameters tested included those describing the 
slow potassium channels, and also the gating of sodium channels and the percentage 
of non-inactivating (persistent) sodium channels, since these have been implicated in 
previous studies (Adelsberger et al. 2000, Sittl et al. 2012). With each parameter 
change, the resting membrane potential was recalculated, since many of the changes 
(especially potassium conductance and persistent sodium conductance) affected the 
resting potential.  
2.6. Statistical analysis 
Post-infusion and recovery nerve excitability parameters were compared within 
individuals, and data from both examinations were compared with data from controls. 
The results of the nerve excitability parameters were correlated to the most common 
symptoms: evoked pain to holding the 6C solid metal cylinder for 10 seconds and 
abnormal sensations (average intensity over the past 24 hours, measured on the NRS). 
Data were analyzed using paired t-tests when comparing post-infusion and recovery 
data, and unpaired t-tests when comparing post-infusion or recovery data with data 
from healthy controls. If data did not follow normal distribution, data were analyzed 
using either Wilcoxon signed rank test for paired data or Mann-Whitney U test for 
unpaired data. Correlations were made by Spearman’s correlation coefficient, except 
that linear correlation was used to assess the percentages of variance accounted for by 
time-adjusted oxaliplatin dose. Fischer’s Exact test and McNemar’s test were used for 
dichotomous data. Stata/IC 12.1 (StataCorp LP, College Station, TX, USA) was used 
for statistical analysis not involving nerve excitability data and Qtrac was used for 
statistical analysis of nerve excitability data. All estimates were expressed as mean ± 
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SD or median and inter quartile range for non-parametric data. p-values < 0.05 were 
considered significant. 
3. Results 
3.1. Clinical characteristics 
A total of 12 patients and 16 healthy controls were recruited for the study. There was 
no difference in the distribution of gender (female patients: 6/12, female controls: 
9/16, p = 0.74), age (patients: 57.2 (11.9) years, controls: 57.8 (11.8) years, p = 0.89), 
height (patients: 172.3 (12.7) cm, controls: 172.8 (9.6) cm, p = 0.91) and weight 
(patients: 78.0 (24.2) kg, controls: 68.5 (14.1) kg, p = 0.20) between patients and 
healthy controls. Clinical characteristics of patients are listed in Table 1.  
All patients reported development of acute neurotoxic symptoms. Eleven patients 
reported abnormal non-painful sensations within the past 24 hours at the post-infusion 
examination with an average intensity of 5.3 (2.5), while this was reported by two 
patients at the recovery examination (Table 2). The most frequent symptoms using the 
oxaliplatin questionnaires after oxaliplatin treatment were tingling paresthesia in the 
hands (100%), feet (42%), and orofacial area (50%), throat discomfort (100%), jaw 
pain (42%), and heavy legs (50%). On the NPSI, pins and needles/tingling were the 
most severe symptom (NRS 3.7 (2.2)) (Table 2). Symptoms were partly reversed at 
the recovery examination, where fewer patients experienced neurotoxic sensory 
symptoms and in all cases to a smaller degree than at the post-infusion examination 
(Table 2). 
 
3.2. Quantitative Sensory Testing (QST) 
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There was no difference in the room or skin temperature at the first and the second 
examination (Room temperature: First 22.3 ± 0.9C, second 22.7 ± 0.9C, p = 0.20. 
Skin temperature: First 34.1 ± 1.0C, second 33.7 ± 0.9C, p = 0.15). Patients 
experienced significantly more pain, unpleasantness, and pricking with cold at the 
post-infusion than at the recovery examination and compared with healthy controls 
(Fig. 1). In addition, patients experienced significantly more pain and unpleasantness 
at the recovery examination than controls (Fig. 1). All patients at the post-infusion 
examination, 82% at recovery examination, and 13% of healthy controls rated the 
cylinder as “freezing cold” rather than cold (p < 0.001 post-infusion vs controls, p = 
0.001 recovery vs controls, and p = 0.02 post-infusion vs recovery). Two patients 
could not hold the cylinder for the full 10 seconds at the post-infusion examination 
(released grip after 3 and 5 seconds respectively).  
CPT was significantly lower (more cold pain sensitive) at the post-infusion compared 
with the recovery examination (16.6 ± 7.9C, 11.6 ± 7.7C, p = 0.02) (Fig. 2). There 
were no differences in other QST parameters (Fig. 2).  
 
3.3. Conventional electrophysiological examinations  
No differences were seen in CMAP or CSAP amplitudes between patients at the post-
infusion and the recovery examination (CMAP: Post-infusion: 13.8 ± 3.5 mV, 
recovery: 14.7 ± 3.7 mV, p = 0.2, CSAP: Post-infusion: 18.1 μV, recovery: 18.6 μV p 
= 0.7) or in comparison with healthy controls (CMAP: 15.1 ± 5.0 mV, p = 0.4, CSAP: 
18.6 μV, p = 0.8). Neither were any differences seen when comparing duration of 
CMAP or CSAP between post-infusion and recovery examinations (CMAP: Post-
infusion: 5.2 ± 0.8 ms, recovery: 5.1 ± 0.8 ms, p = 0.8, CSAP: Post-infusion: 0.7 ± 0.1 
ms, recovery: 0.7 ± 0.1 ms, p = 0.8) or in comparison with healthy controls (CMAP: 
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5.2 ± 0.8 ms, p = 0.7, CSAP: 0.8 ± 0.2 ms, p = 0.5). The results indicate no axonal 
loss in the acute phase after oxaliplatin administration.  
There were no signs of repetitive discharges in CSAPs. In contrast, nine patients 
showed repetitive motor discharges in post-infusion recordings.  
 
3.4 Nerve excitability tests 
3.4.1. Motor nerve excitability 
Motor nerve excitability measurements were compared between controls, post-
infusion and recovery groups in Table 3, and excitability waveforms are illustrated in 
Fig. 3A-D. The most conspicuous difference between the post-infusion and recovery 
measurements for the 11 patients for whom paired comparisons could be made were 
in the higher thresholds during the recovery cycle (Fig. 3D), with a highly significant 
reduction in superexcitability (p=0.00013) and increase in late subexcitability 
(p=0.0032) in the post-infusion examinations. The post-infusion recordings also had 
higher electrical threshold and rheobase and lower strength-duration time constant. In 
all of these changes, the recovery recordings were closer to the healthy controls than 
the post-infusion recordings. The differences in superexcitability and subexcitability 
between post-infusion recordings and healthy controls are shown by the scatter plot in 
Fig. 3E.  There is a small overlap, but the post-infusion recordings differed so 
substantially from the healthy controls that they could be separated completely by 
several pairs of excitability measurements, e.g. superexcitability(%) vs peak 
depolarizing electrotonus (Fig 3F), while the recovery measurements bridged the two 
groups.  
3.4.2. Sensory nerve excitability 
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Table 4 and Figure 4A-D show the sensory nerve excitability measurements 
corresponding to the motor excitability measurements in Table 3 and Fig. 3A-D. 
Although there was a significant increase in superexcitability between the post-
infusion and recovery recordings, the similarity in mean post-infusion values of 
superexcitability and subexcitability to the healthy controls was in marked contrast to 
the motor nerves.  The scatter plots in Figs. 4E and 4F, plotted with similar scaling as 
Figs. 3E and 3F, show that the failure to detect a post-infusion abnormality in the 
sensory nerves was not due to any increased variability in the sensory recordings. 
However, like the motor axons, threshold and rheobase were higher for the post-
infusion examination, while strength-duration time constant was shorter.   
3.4.3. Motor nerve recovery cycle and repetitive discharges 
One possible explanation for the changes in recovery cycle induced by oxaliplatin in 
motor fibres is that normal impulse transmission is disrupted by repetitive discharges 
originating in the nerve terminals, which can resemble neuromyotonia (Wilson et al., 
2002). To test this possibility, we compared the early changes in the recovery cycle 
with the repetitive discharges evoked by the supramaximal conditioning stimuli. 
Examples are illustrated in Figure 5.  In the top row, showing superimposed 
waveforms to 50 supramaximal stimuli, the small circles indicate the first clear 
repetitive discharges, whereas the large circles indicate F responses. The distances 
between the vertical lines, indicating the latencies of the first repetitive discharges, 
averaged 4.8 ± 1.5 ms (mean ± SD, range 3.2 - 7.3 ms) for the 9 post-infusion patients 
showing multiple action potentials.  In each case, the thresholds in the recovery cycle 
were abnormally high before this interval, and therefore before any collision with an 
antidromically conducted impulse was possible. Also, it can be seen that the 
proportion of motor axons discharging repetitively was small, comparable with those 
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generating F responses, so that any effect of the collisions on thresholds would also be 
small  (see Discussion).   
Figure 5 (bottom row) also compares the recovery cycles following oxaliplatin 
treatment with the recovery cycles following two conditioning stimuli, 4 ms apart 
(open triangles). They show a clear similarity in waveform, with the example in Fig. 
5B superimposed almost perfectly on the mean recovery cycle after two 
supramaximal conditioning stimuli. This remarkable correspondence suggests that 
very similar membrane changes are involved. The difference between recovery cycles 
with one and multiple conditioning stimuli is known to depend primarily on the 
activation of slow potassium currents (Bergmans, 1970; Schwarz et al., 2006). The 
results in Fig. 5 therefore indicate that neither the timing nor extent of repetitive 
discharges could account for the changes in motor recovery cycles, but that these 
could be explained by additional activation of slow potassium currents at the site of 
stimulation. To understand how this could have occurred, we used mathematical 
modeling to explore how oxaliplatin could change the axonal membrane properties to 
bring this about. 
3.4.4. Modeling of motor nerve excitability changes 
The extent of the discrepancy reductions are illustrated in Figure 6E for those 
parameters that reduced the discrepancy by 1% or more. (N.B. The percentage of 
persistent sodium channels does not occur in this list, since changing this parameter 
did not reduce the discrepancy at all.) It can be seen that much the best improvement 
in fit was achieved by a change in Aah, the rate of inactivation of sodium channels. 
Reducing this rate by 37.3% reduced the discrepancy by 62.5%, whereas no other 
single parameter changed reduced the discrepancy by more than 12%. The changes in 
the model excitability waveforms produced by slowing sodium channel inactivation 
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by 37% are illustrated in Figure 6A-E, and show a highly selective action on the 
recovery cycle. 
The effects of slowing sodium channel inactivation on the recovery cycle are shown 
in more detail in Figure 7. Fig. 7A shows the recovery cycles of the 12 post-infusion 
recordings superimposed, and Fig. 7B shows modeled recovery cycles for inactivation 
rates from 90% to 30% of normal. Slowing sodium channel inactivation slows the 
recovery phase of the action potential, thus broadening it (Fig. 7C), and increasing the 
activation of slow (Kv7) potassium channels, which causes an increased 
hyperpolarizing afterpotential (Fig. 7D), reduced superexcitability and increased late 
subexcitability. 
If oxaliplatin selectively slows sodium channel inactivation in motor fibres, one might 
expect it to also slow sodium channel inactivation in sensory fibres, since the major 
sodium channel isoform in each case is Nav1.6 (Caldwell et al., 2000). However, 
applying similar changes in the parameter Aah in the model for sensory fibres 
(Howells et al., 2012) produced changes in the sensory nerve recovery cycle similar to 
those in Fig. 6, in contrast to the recorded recovery cycles (Fig. 4). 
 
3.5. Correlations 
3.5.1. Motor nerve superexcitability, subexcitability and acute sensory symptoms 
The sensory abnormalities that best distinguished the post-infusion from recovery 
examinations, with the greatest difference in median NRS (scale 1-10) and by 
Wilcoxon signed rank test, were the responses to the cold cylinder as in Fig. 1 and the 
average of unpleasant sensations over 24 hours. These NRS values at the first 
examination each correlated significantly with motor axon superexcitability: average 
unpleasantness (Rho=0.797, p=0.0020), cold cylinder pricking (Rho=0.640, p=0.024), 
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cold cylinder pain (Rho=0.628, p=0.028), cold cylinder unpleasantness (Rho=0.640, 
p=0.024).  The corresponding figures for motor axon late subexcitability were: 
average unpleasantness (Rho=0.762, p=0.0040), cold cylinder pricking (Rho=0.685, 
p=0.014), cold cylinder pain (Rho=0.670, p=0.017), cold cylinder unpleasantness 
(Rho=0.685, p=0.014). 
3.5.2. Superexcitability, sensory symptoms and time-adjusted oxaliplatin dose 
The range of different acute drug effect on superexcitability shown in Fig. 7A seemed 
surprising, considering that the measurements followed single doses that only varied 
between 94 and 136 mg/m2.  Previous studies have shown that the cold allodynia 
induced by oxaliplatin declines over a period of days. To help to explain the 
differences in superexcitability, we assumed a simple model in which the change was 
initially proportional to the dose and decayed exponentially, described by a half-life 
of h days. On this model, the time adjusted dose D should be related to the original 
dose D by the relationship D = D×2(-t/h) where t is the time in days after infusion. For 
the second and subsequent infusion, this expression should be summed over all 
infusions, i.e. time-adjusted total dose = ∑ D×2(-t/h). Using this relationship, we 
calculated the linear correlations between superexcitability and time-adjusted total 
dose per surface area for half-times between 1 and 50 days, using the data from all the 
23 patient examinations (Figure 8A). There was a broad maximum in the correlations, 
peaking at a half-life of 7-10 days. Fig. 8C shows the scatter plot of values for 
superexcitability and estimated dose/m2 for a half-life of 10 days. The correlation 
coefficient was 0.813, indicating that this relationship accounts for 66% of the 
variance in superexcitability, and the regression line cuts the y axis at a 
superexcitability of -24.5%, close to the value expected for a zero dose, since 
superexcitability in the healthy controls averaged -23.2%.  
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Fig. 8B shows similar calculations for the two most abnormal sensations induced by 
oxaliplatin: cold cylinder pricking and average unpleasant sensations over 24 hours. 
In each case, the correlation with time-adjusted oxaliplatin dose was highest for a 
half-life of about 10 days. The correlation reached a value of 0.957 for cold cylinder 
pricking, indicating that 92% of the variance in this measurement was accounted for 
by this simple model. Comparison between Fig. 8A and Fig. 8B shows that there is a 
good correspondence in the time course of the effect of oxaliplatin on sodium channel 
inactivation and the time course of its effect on acute neurotoxic symptoms. 
3.5.3. Sensory nerve excitability and acute sensory symptoms 
In contrast to the correlations with motor nerve excitability changes, we found no 
significant correlations between pain from holding the cylinder or intensity of 
abnormal sensations and sensory axonal excitability. The correlation coefficients and 
p-values for post-infusion superexcitability correlated to holding the cylinder are: 
average unpleasantness (Rho= -0.032, p=0.922), cold cylinder pricking (Rho=0.026, 
p=0.936), cold cylinder pain (Rho=0.038, p=0.908) and cold cylinder unpleasantness 
(Rho=0.026, p=0.936).   
  
4. Discussion 
There have already been a number of papers describing nerve excitability studies in 
patients receiving oxaliplatin treatment (Krishnan et al. 2005, 2006; Park et al. 2009a, 
2009b, 2011; McHugh et al. 2012). Where this study breaks new ground is a) in 
providing evidence for the role of slowed sodium channel inactivation in the changes 
in motor nerve excitability, b) in demonstrating the close relationship between the 
acute changes in the motor nerve recovery cycle and the acute sensory symptoms, and 
c) in relating both of these acute changes to the patient treatment history. 
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This study has confirmed the paradoxical nature of the acute effects of oxaliplatin on 
nerve excitability: although it is a sensory hyperexcitability that is the most serious 
acute side-effect of oxaliplatin treatment, it is motor axons that display the most 
marked excitability abnormalities. The reversible changes in the recovery cycle of 
motor axons were very similar to those previously described by Krishnan and 
colleagues (Krishnan et al., 2005, 2006), although we did not find significant changes 
in RRP. (This comparative lack of sensitivity may have been in part because we made 
no baseline examinations, so we were unable to compare pre- and post-infusion 
recordings directly, in part because of the variable timing of the post-infusion 
recordings (1-3d) and in part because of the limited number of patients). Park and 
colleagues (Park et al., 2009b) demonstrated more subtle acute effects of oxaliplatin 
on sensory fibres. We found an increase in sensory superexcitability between the 1st 
and 2nd examinations, but no significant differences from healthy controls. The 
sensory changes indicated by Park et al. were cumulative, rather than reversible, and 
after many drug cycles were clearly related to the chronic sensory neuropathy.  
Although the recovery cycle changes were quite different between motor and sensory 
fibres, some excitability changes were similar: thresholds and rheobases were 
significantly increased at post-infusion and partly normalized at recovery, whereas 
SDTCs were significantly reduced post-infusion. Since these excitability parameters 
are those most dependent on current access to the axons, and did not correlate with the 
other, dose-dependent excitability measurements, interpretation is uncertain.  
 
4.1. Biophysical basis of changes in motor nerve excitability 
Krishnan et al. (2005, 2006) found that oxaliplatin induced an increase in 
refractoriness in motor axons, without changes in threshold electrotonus or SDTC, 
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and concluded that oxaliplatin neurotoxicity is mediated through an effect on nodal 
voltage-gated sodium channels.  Park et al. (2009b) confirmed the increase in 
refractoriness in motor axons, but found a contrasting decrease in refractoriness in 
sensory axons. In seeking an explanation for this discrepancy they noted that 
oxaliplatin has been shown to induce 'neuromyotonic-type' discharges in motor axons 
(Wilson et al., 2002).  They suggested that these might account for the increased 
refractoriness at short inter-stimulus intervals, since Kuwabara et al. (2001) reported 
that the refractory period of transmission in normal human motor fibres is prolonged 
by a period of maximal voluntary contraction.  However, the repetitive discharges in 
neuromyotonia are not associated with any increase in refractoriness (Kiernan et al., 
2001). Also, the voluntary activity employed by Kuwabara and colleagues generated 
an increase in superexcitability, contrasting with the decrease with oxaliplatin. An 
alternative possibility would be that oxaliplatin-induced repetitive discharges from the 
motor nerve terminals might raise thresholds during the recovery cycle by colliding 
with the test volley. We have investigated this possibility (Fig. 5) and found that the 
repetitive discharges only occur after an interval of ca 5 ms, too late to account for the 
early increase in refractoriness.    
In oxaliplatin-treated patients, the proportion of motor axons giving a repetitive 
discharge to the supramaximal conditioning stimuli was small (Fig. 5, top row), so the 
antidromic impulses could only have produced a small reduction in superexcitability 
and increase in late subexcitability. (N.B. Because of the high slope of the stimulus-
response curve for motor fibres, a 5% reduction in the number of fibres conducting a 
second impulse, due to collision with a repetitive discharge, would only be expected 
to increase threshold by about 1%).  The characteristic elevation of the whole of the 
recovery cycle (increased refractoriness, reduced superexcitability and increased late 
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subexcitability), which was seen even when there were no repetitive discharges, (as 
was the case in nearly all of the 2nd examination recordings) requires a different 
explanation.  
Studies of the effects of oxaliplatin on rodent neuronal preparations have provided 
evidence for a variety of changes in action potentials or sodium channel gating:  
Adelsberger et al. (2000) reported that the most pronounced effect of oxaliplatin on 
dorsal root ganglion (DRG) cells was a slowdown of the inactivation kinetics of 
sodium channels; Sittl et al. (2012), recording from cultured mouse DRG neurons, 
found enhanced resurgent and persistent sodium currents on cooling in the presence of 
oxaliplatin. When we modeled the effects of changes in membrane properties on 
motor nerve excitability, we found that slowing of sodium channel inactivation 
kinetics alone provided a satisfactory explanation of our patient recordings, since the 
broadened action potentials had a similar effect on the recovery cycle to a second 
conditioning impulse, without appreciable effect on electrotonus (Figs. 6,7). The 
puzzling question of why similar changes were not seen in the large sensory fibres is 
considered further below (section 4.4). 
4.2. Correlation between acute motor nerve changes and acute sensory 
symptoms 
The most severe symptoms of oxaliplatin neurotoxicity are sensory, so it is important 
to establish how closely the easily measureable acute changes in motor axons are 
related to the acute sensory symptoms. A novel feature of this study is that it is the 
first to combine QST, pain questionnaires and cold cylinder tests of cold allodynia 
with nerve excitability studies. The measurements made in this study were at different 
times (1-3 and 15-20 days, one patient 53 days) after different oxaliplatin doses (94-
136 mg/m2), and sensory symptoms were compared with motor nerve 
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superexcitability over these differing treatments. The results show significant 
correlations, especially with the average unpleasantness, for which half the variation 
at the first examination was accounted for by the correlation with superexcitability 
(Rho = 0.797).  This correlation was maintained over the 23 observations in both 
examinations (Rho=0.783). The correlation between superexcitability and pricking 
pain with the cold cylinder was also significant (1st examination Rho=0.640, both 
examinations Rho=0.786). This, and the fact that the two phenomena decay over a 
similar time course (see below), suggest that sodium channel dysfunction may also be 
responsible for the cold allodynia.   
4.3. Relation between acute neurotoxicity and dose history 
Another novelty of this study is that the effect of an oxaliplatin dose on motor 
superexcitability can be modeled quite well on the simple assumption that excitability 
changes are proportional to the dose/m2 but decay with a half-life of about 10 days 
(Fig. 8). Moreover, the same model accounts remarkably well for the variation in 
NRS scores for cold allodynia. The origin of the long half-life of the oxaliplatin-
modified sodium channels is not clear: it might be related to slow dissociation of the 
oxaliplatin-channel complex, or possibly to the normal turnover rate for peripheral 
nerve Na channels. Interestingly, although most ultrafiltrable platin is removed from 
the blood within a day or two (Kern et al., 1999), a 'terminal elimination phase' can be 
detected with a half-life of 237 hours (Morrison et al., 2000), close to the apparent 
half-life of the acute neurotoxicity. 
Although the correlation coefficients in Fig. 8C,D are high, the confidence limits for 
the regression lines indicate that a considerable degree of inter-patient variability is 
not accounted for by the time-adjusted dose. Ehrsson et al. (2002) found a coefficient 
of variation of only 14% for serum oxaliplatin levels for the same dose/m2. Other 
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sources of variation may include differences in access to the axons across the blood-
nerve barrier and genetic polymorphisms, as well as the variation intrinsic in 
individual measurements. 
4.4. Differences in oxaliplatin sensitivity of motor and large sensory axons 
A puzzling feature of oxaliplatin neurotoxicity, as already mentioned, is that sodium 
channels in motor axons in the nerve trunk, underneath the stimulating electrode, have 
their rate of inactivation slowed, whereas nearby sodium channels in Aβ large sensory 
axons in a similar environment are less affected. There is clear evidence, however, 
that the major sodium channel isoform at nodes of Ranvier in both motor and sensory 
axons is Nav1.6 (Caldwell et al., 2000). Differential access to the two axon types 
seems unlikely, and this raises the possibility that accessory subunits or other channel-
binding proteins may differ between nodes in sensory and motor axons and affect the 
affinity of the Nav1.6 channels for oxaliplatin. Direct evidence comparing the 
sensitivity of motor and sensory mammalian axons to oxaliplatin is not available in 
the literature. The oxaliplatin concentrations within the nerve fascicles are unknown, 
but must be less than the serum concentrations, which according to Ehrsson et al. 
(2002) reach a maximum of 1.44 μg/ml (=3.6 μM) for a dose of 85 mg/m2, 
corresponding to  4.0-5.8 μM for the dose range (94-136 mg/m2) in this study. The 
only animal studies reporting action potential broadening at such a low concentration 
were those of Kagiava et al. (2008, 2013). They recorded intracellularly from rat 
sciatic axons and found broadened action potentials with oxaliplatin concentrations as 
low as 5 μM, but their preparation did not allow distinction between motor and 
sensory axons. Studies on sensory mammalian nerves have used higher 
concentrations: Adelsberger et al. (2000) recorded broadened rat sural nerve action 
potentials with 250 μM oxaliplatin; Sittl et al. (2010) used lower concentrations of 
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oxaliplatin (10-30 μM) in an organ bath, and tested isolated fascicles of human as 
well as rat sural nerves, but only reported broadened action potentials and after-
activity with 30 μM oxaliplatin.  Sittl et al. (2012) also found an increase in 
depolarizing threshold electrotonus in desheathed mouse sural nerve exposed to 100 
μM oxaliplatin, suggestive of increased persistent sodium currents and correlated with 
repetitive activity. 
So further animal experiments are required to resolve the question of whether motor 
and sensory nodes in the nerve trunk have a different sensitivity to oxaliplatin, as our 
results seem to apply. As to how such a difference in sensitivity could arise, one 
possibility could be competitive binding by the fibroblast growth factor homologous 
factor 2B (FHF2B), which is colocalized with Nav1.6 at mature nodes of Ranvier in 
dorsal root sensory, but not ventral root motor axons (Wittmack et al., 2004), but 
other possible mechanisms also needs to be explored. 
Although the sensory nerve excitability measurements showed no evidence of altered 
sodium channel gating with oxaliplatin, sensory symptoms are more prominent and 
reported by a greater fraction of patients than motor symptoms. Although we cannot 
exclude methodological causes such as technical difficulties in assessing sensory 
fibers or the relatively low number of subjects, which is a limitation of this study, this 
may in part be accounted for by the occurrence of Aδ-mediated painful sensations, but 
patients also report tingling and buzzing sensations, indicating involvement of Aβ 
fibers. Spontaneous activity in Aβ fibres would not be detectable in our nerve 
excitability recordings, just as they are not visible in conventional NCS (Campero et 
al., 1998). 
The difference between motor and sensory axons is as marked in their sensitivity to 
chronic neurotoxicity as it is to the acute neurotoxicity. In chronic neurotoxicity it is 
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tingling and numbness, caused by Aβ fibres loss, that are the worst symptoms 
(Pachman et al., 2015). In this and other respects, the chronic oxaliplatin neurotoxicity 
resembles that induced by cisplatin and other platins, which do not have a specific 
action on sodium channels, but which accumulate in DRG neurones and may damage 
the cells by binding to DNA (Ta et al., 2006; Park et al., 2013), or by interfering with 
microtubule-based axonal transport (Higa et al., 2016). 
4.5. Motor nerve superexcitability as a biomarker for oxaliplatin neurotoxicity? 
Several studies have shown that sensitivity to acute oxaliplatin neurotoxicity 
correlates well with sensitivity to chronic neurotoxicity (Pachman et al., 2014; 
Pachman et al., 2015). In the most long-lasting study, Pachman and colleagues 
(Pachman et al., 2015) found a good correlation between acute symptoms during the 
first treatment cycle and the chronic sensory neurotoxicity up to 18 months after 
cessation of chemotherapy. Nerve excitability measurements are extremely sensitive 
to the changes in sodium channels responsible for the acute neurotoxicity, and it has 
reasonably been proposed that they may therefore provide an objective biomarker for 
the risk of developing chronic nerve damage (Krishnan et al., 2006). While our data 
strongly support their proposal, it does not follow that prophylactic strategies to 
reduce the acute neurotoxicity by mitigating the effects on sodium currents can be 
expected to avert the chronic neurotoxicity. This is because the mechanisms may be 
quite different, as discussed in the previous paragraph. However, one should 
remember the small sample size in our study, which limits making clear conclusions. 
Further studies with larger patient groups are warranted.  
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Fig. 1. Intensity of pain, unpleasantness and pricking with holding a cold metal 
cylinder (approximately 6C) for 10 seconds.  
Boxes: interquartile range, whiskers: 10% and 90% percentiles. NRS: Numeric rating 
scale. * p < 0.05 ** p < 0.01 *** p < 0.005. 
 
Fig. 2. Multiple error bars plot of mean z-score ± SD for QST parameters at post-
infusion and recovery examination.  
CDT: cold detection threshold; WDT: warm detection threshold; TSL: thermal 
sensory limen; CPT: cold pain threshold; HPT: heat pain threshold; MPT: mechanical 
pain threshold; VDT: vibration detection threshold. * p < 0.05. 
 
Fig. 3. Motor nerve excitability recordings. Curves: Mean of patients (n = 11), 
controls (n = 16). Healthy controls (open circles), patients with post-infusion 
examination (filled triangles), and patients with recovery examination (open squares). 
A) Current/threshold (I/V) relationship, B) Strength-duration time constant, C) 
Threshold electrotonus, D) Recovery cycle, E) Subexcitability (%) plotted against 
superexcitability(%) for post-infusion and healthy controls only, F) Peak depolarizing 
electrotonus TEd(peak) plotted against superexcitability(%) for all three groups. In E 
and F the polygons join the limits of the groups. 
 
Fig. 4. Sensory nerve excitability recordings, plotted as for the motor nerves in Fig. 3. 
Curves: Mean of patients (n = 11), controls (n = 16). Healthy controls (open circles), 
patients with post-infusion examination (filled triangles) and patients with recovery 
examination (open squares). A) I/V relationship, B) Strength-duration time constant, 
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C) Threshold electrotonus, D) Recovery cycle., E) Subexcitability plotted against 
superexcitability for post-infusion and healthy controls only, F) Peak depolarizing 
electrotonus TEd(peak) plotted against superexcitability for all three groups. 
 
Fig. 5. Comparison between repetitive discharges and recovery cycles of motor fibres.  
Top row: Superimposed CMAP responses to 50 supramaximal conditioning stimuli 
illustrated for two post-infusion recordings (A,B) and one recovery recording (C). 
Small circles indicate first indication of a repetitive discharge (barely visible in C); 
large circles indicate F-waves.  Vertical lines indicate action potential peaks, with 
separations 7.6 (A), 4.0 (B) and 6.6 ms (C).  Bottom row: Recovery cycles from same 
recordings as in top row (filled black circles).  Open grey circles and dashed lines 
indicate mean ± SD for RCs of healthy controls (n=16).  Open triangles and dashed 
lines indicate mean ± SD for RCs of healthy controls with 2 conditioning stimuli 
(n=8). Note (a) that abnormal elevation of post-infusion RCs starts before thresholds 
could be affected by repetitive discharges, and (b) that post-infusion RC in B is 
indistinguishable from mean RC of healthy controls with 2 conditioning stimuli. 
 
 
Fig. 6. The changes in the model excitability waveforms produced by slowing sodium 
channel inactivation by 37% are illustrated in Figure 6A-E, and show a highly 
selective action on the recovery cycle. Effect on model of healthy control data (gray) 
of slowing Na channel inactivation by 37% (black) is shown for I/V relationship (A), 
strength-duration time constant (B), threshold electrontonus (C) and recovery cycle 
(D). E shows the best discrepancy reductions between healthy control model and post-
infusion data obtainable by changing single model parameters. (Aah = rate constant 
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Na channel inactivation, Aas = rate constant slow K channel activation, Cah = slope 
factor Na channel inactivation, GKsN =  conductance nodal slow K channels, Bah = 
half-activation voltage Na channel inactivation, Aam = rate constant Na channel 
activation, Bq = half-activation voltage HCN channels, GKfN = conductance nodal 
fast K channels, GH = conductance HCN channels, Can = slope factor fast K 
channels, Cam = slope factor Na channel activation, PNaN = permeability nodal Na 
channels, Bam = half-activation voltage Na channel activation, GLk = internodal leak 
conductance, GBB = Barrett-Barrett conductance) 
 
Fig. 7. The effects of slowing sodium channel inactivation on the recovery cycle. A) 
The recovery cycles of the 12 post-infusion recordings superimposed, B) Modeled 
recovery cycles for inactivation rates from 90% to 30% of normal, C,D) Modeled 
action potential waveforms corresponding to recovery cycles in B, with different 
scaling to show action potential broadening (C) and increased positive afterpotentials 
corresponding to subexcitability (D).  Action potentials truncated in D.  
 
Fig. 8. Correlation coefficient for correlations between total time-adjusted dose of 
oxaliplatin and A) superexcitability, B) The two most abnormal sensations induced by 
oxaliplatin. C and D show scatter plots of values for superexcitability and cold 
cylinder pricking, respectively, versus estimated dose/area for a half-life of 10 days. 
Filled symbols indicate post-infusion examination and open symbols indicate 









n(%) or        
mean ±SD 
  
Females 6 (50) 
Age (years) 57.2 ± 12 
Height (cm) 172.3 ± 13 
Weight (kg) 78.0 ± 24 
Disease stage  
   II 3 (25) 
   III 8 (67) 
   IV 1 (8) 
Treatment cycles  
   1 cycle 
   2 cycles 




Single dose (mg) 220.3 ± 39 
Patients receiving full dose (130 mg/m2) 9 (75) 
Patients receiving reduced dose (97.5 mg/m2) 3 (25) 
Patients reduced in dose 4 (33) 
   Due to neuropathy 0 (0) 
   Incomplete post-operative recovery 4 (33) 
Examination, days after treatment  
   1 day 5 (42) 
   2 days 2 (17) 









(n(%) or  
mean ± SD) 
Recovery 
examination 
(n(%) or  
mean ± SD) 
   
Patients (n) 12 11 
Patients with pain (24hrs) 4 (33) 0 (0.0) 
   Hands 2 (17) - 
   Feet 1 (9) - 
   Throat 2 (17) - 
Intensity of pain,(NRS)* 3.8 ± 2 - 
Patients with abnormal sensations (24hrs) 11 (92) 2 (18) 
   Hands 11 (92) 1 (9) 
   Feet 4 (33) 0 (0) 
   Throat 10 (83) 1 (9) 
Intensity of abnormal sensations (NRS)* 5.3 ± 3 1.5 ± 0.7 
Most common symptoms in upper extremity**   
   Tingling or pins and needles 12 (100) 5 (45) 
   Burning pain or discomfort with cold 11 (92) 5 (45) 
Most common symptoms in lower extremity**   
   Tingling or pins and needles 5 (42) 1 (9) 
   Burning pain or discomfort with cold 3 (25) 0 (0) 
   Heavy legs 6 (50) 2 (18) 
Most common symptoms in face/mouth**   
   Jaw pain 5 (42) 0 (0) 
   Throat discomfort 12 (100) 5 (45) 
   Tingling in mouth 6 (50) 1 (9) 
   Burning pain or discomfort in eyes 4 (33) 0 (0.0) 
   Difficulty with speech 4 (33) 0 (0.0) 
NPSI score (0-100)***  22.3 ± 16 1.0 ± 2 
   Evoked pain (0-10) 2.6 ± 3 0.2 ± 0.3 
   Pressing (deep) spontaneous pain (0-10) 0.5 ± 0.8 0.0 ± 0 
   Paroxysmal pain (0-10) 3.0 ± 3 0.1 ± 0.3 
   Pins and needles/tingling (0-10) 3.7 ± 2 0.1 ± 0.2 
   Burning superficial pain (0-10) 0.8 ± 2 0.0 ± 0 
   
*Mean intensity and sd of patients who reported pain and paresthesia.  
**Oxaliplatin-specific questionnaire 











(n = 16) 
Patients     
post-infusion 
(n = 11)a 
Patients     
recovery 
(n = 11)a 
Difference       
(n = 11)b 
Stimulus-response and strength-duration properties 
Stimulus (mA) 
for 50% maximal CMAPc 
4.74 ×/ 1.08 6.97 ×/ 1.12** 5.78 ×/ 1.1 1.21 ×/ 1.06** 
Peak CMAP (mV)c 8.83 ×/ 1.08 9.05 ×/ 1.11 8.74 ×/ 1.09 1.04 ×/ 1.09 
Strength-duration time 
constant (ms) 
0.46 ± 0.02  0.41 ± 0.02 0.49 ± 0.03 -0.08 ± 0.02** 
Rheobase (mA)c 3.1 ×/ 1.09 4.77 ×/ 1.13** 3.72 ×/ 1.1* 1.28 ×/ 1.06** 
Threshold electrotonus 
TEd40(peak) (%) 67.61± 1.3 68.5 ± 1.0 67.8 ± 0.7 0.7 ± 1.1 
TEd40(90-100ms) (%) 42.9 ± 0.8 45.2 ± 1.0 44.0 ± 0.7 1.2 ± 0.7 
TEd20(peak) (%) 37.9 ± 1.1 38.9 ± 0.9 38.2 ± 0.5 0.7 ± 0.9 
TEd(undershoot)(%) -20.1 ± 1.0 -17.9 ± 0.6 -19.3 ± 0.8 1.4 ± 0.8 
TEh40(20-40ms) (%) -93.2 ± 2.5 -95.1 ± 2.9 -97.8 ± 2.7 2.6 ± 2.7 
TEh40(90-100ms) (%) -118.9 ± 5.8 -129.6 ± 7.1 -124.5 ± 4.5 -5.0 ± 4.2 
Current-threshold properties 
Resting I/V slope 0.591 ± 0.020 0.557 ± 0.022 0.572 ± 0.013 -0.015 ± 0.019 
Minimum I/V slope 0.259 ± 0.013 0.281 ± 0.014 0.262 ± 0.015 0.019 ± 0.006** 
Hyperpolarising I/V slope   0.394 ± 0.012 0.441 ± 0.017* 0.411 ± 0.015 0.030 ± 0.014 
Recovery Cycle 
RRP (ms) c 3.13 ×/ 1.03 3.33 ×/ 1.04 3.12 ×/ 1.02 1.55 ×/ 1.43 
Superexcitability (%)    -23.2 ± 1.7 -10.2 ± 1.9**** -19.8 ± 1.1 9.6 ± 1.6*** 
Subexcitability (%)       14.2 ± 0.9 23.2 ± 2.5*** 15.1 ± 1.9 8.0 ± 2.1** 
     
Comparison between nerve excitability measurements in motor axons of patients and 
controls. Values are mean + SEM, except for 3 measurements (indicated by c) which 
were normalized by log conversion and values are geometric mean ×/ standard error 
expressed as a factor. TEd40(peak)% = Peak percentage threshold reduction in 
threshold electrotonus with depolarizing current, 40% of unconditioned threshold. 
TEh40(20-40ms) = Mean threshold reduction 20-40 ms after start of 40% 
hyperpolarizing current. RRP = relative refractory period.  
a Asterisks indicate probability of difference from healthy controls by two-tailed t-test. 
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b Asterisks indicate probability of difference between two patient recordings by two-
tailed paired t-test. 








(n = 16) 
Patients     post-
infusion 
(n = 11)a 
Patients     
recovery 
(n = 11)a 
Difference       
(n = 11)b 
Stimulus-response and strength-duration properties 
Stimulus (mA) 
for 50% maximal CSAPc 
4.80 ×/ 1.06 6.48 ×/ 1.10** 5.34 ×/ 1.07* 1.21 ×/ 1.06* 
Peak CSAP (μV)c 28.1 ×/ 1.12 36.3 ×/ 1.62 21.0 ×/ 1.18 1.73 ×/ 1.70 
Strength-duration time 
constant (ms) 
0.566 ± 0.015  0.464 ± 0.025** 0.566 ± 0.04 -0.10 ± 0.03** 
Rheobase (mA)c 2.07 ×/ 1.07 3.19 ×/ 1.13** 2.37 ×/ 1.08* 1.35 ×/ 1.08** 
Threshold electrotonus 
TEd40(peak) (%) 61.7 ± 0.8 62.9 ± 0.7 62.3 ± 0.8 0.6 ± 0.9 
TEd40(90-100ms) (%) 48.1 ± 1.1 47.6 ± 1.2 47.5 ± 1.0 0.1 ± 1.2 
TEd20(peak) (%) 41.7 ± 1.4 41.2 ± 0.9 42.2 ± 1.3 -1.0 ± 1.1 
TEd(undershoot)(%) -20.7 ± 0.9 -19.5 ± 0.5 -21.6 ± 0.9 2.1 ± 0.7* 
TEh40(20-40ms) (%) -107.8 ± 3.3 -107.2 ± 3.4 -111.5 ± 4.6 4.3 ± 2.3 
TEh40(90-100ms) (%) -140.6 ± 6.5 -144.4 ± 5.5 -149.0 ± 7.6 4.5 ± 3.6 
Current-threshold properties 
Resting I/V slope 0.546 ± 0.018 0.550 ± 0.028 0.572 ± 0.013 -0.003 ± 0.013 
Minimum I/V slope 0.245 ± 0.011 0.277 ± 0.012 0.262 ± 0.015 0.019 ± 0.010 
Hyperpolarising I/V slope   0.457 ± 0.033 0.464 ± 0.029 0.411 ± 0.015 0.005 ± 0.029 
Recovery Cycle 
RRP (ms) c 3.49 ×/ 1.05 2.95 ×/ 1.06* 3.12 ×/ 1.02 0.94 ×/ 1.06 
Superexcitability (%)    -16.8 ± 1.5 -16.6 ± 1.5 -19.6 ± 0.7 3.0 ± 1.2* 
Subexcitability (%)       10.0 ± 0.6 10.5 ± 0.8 15.1 ± 1.9 1.3 ± 0.9 
     
Comparison between nerve excitability measurements in sensory axons of patients 
and controls. Values are mean + SEM, except for 3 measurements (indicated by c) 
which were normalized by log conversion and values are geometric mean ×/ 
standard error expressed as a factor. CSAP = compound sensory action potential. 
Other abbreviations as in Table 3. 
a Asterisks indicate probability of difference from healthy controls by two-tailed t-test. 
b Asterisks indicate probability of difference between two patient recordings by two-
tailed paired t-test.  a,b * = P < 0.05, ** = P < 0.01. 
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